pharmacy for Sale

Median pharmacy sale prices increased from $262,500 in 2021 to $600,000 in 2025, while median revenue grew from $675,000 to $2.5 million over the same period. This suggests that higher sale prices are being driven primarily by larger pharmacies entering the market rather than by buyers paying higher valuation multiples for similar businesses. For individual buyers, this distinction matters. The median transaction may not be representative of a small independent pharmacy in a residential neighborhood. More meaningful comparisons come from pharmacies with similar revenue, prescription volume, payer mix, and operating characteristics.

Discretionary earnings as a percentage of revenue dropped to 7.3% in 2025, down from 18.4% in 2024. The compression reflects structural PBM reimbursement pressure that has reduced the spread on dispensed prescriptions, plus rising operating costs that haven't been offset by reimbursement increases. Buyers should not assume historical margins continue forward. A pharmacy that ran 15% SDE margins in 2022 may run 7-8% today on the same revenue. Underwrite to current reimbursement environment, not historical performance.

Common rules of thumb: 18-22% of gross sales; $200-$400 per active prescription. A pharmacy doing $2M in revenue with $200K in SDE might value between $400K (revenue multiple) and $700K (SDE multiple). The right number depends on the pharmacy's quality factors: payer mix (more cash and commercial, less Medicare/Medicaid is better), niche services (compounding, long-term care, 340B), script-file age (fresh prescriptions and active patients vs old, dormant records), and growth trajectory. Buyers should triangulate across methods.

Compounding pharmacies, long-term care pharmacies, 340B-eligible pharmacies, and pharmacies with strong clinical service programs (vaccinations, MTM, diabetes management) trade at premiums over generic retail pharmacies. Niche pharmacies generate higher gross margins (compounding can run 40-60%+ vs 18-22% for typical retail) and have less PBM exposure on specialty work. A buyer evaluating a pharmacy should identify any niche capabilities, understand the revenue and margin contribution, and value those separately from the underlying retail dispensing business.

A typical pharmacy carries $150,000-$500,000 in inventory at any time. Pharmacy inventory turns 8-12 times per year. Inventory is usually a separate negotiation from the business value, paid at landed cost or at agreed adjustments. Controlled substances inventory requires specific transfer protocols (DEA Form 222 and similar). Expiring inventory is the buyer's risk if not separately negotiated. Business buyers should do an inventory walk-through with the seller and document what's near expiration and what's slow-moving.

Many pharmacies operate from leased space; some include owned real estate. Lease economics matter enormously as pharmacies are foot-traffic businesses, and a pharmacy with a strong lease in a high-visibility location is worth more than the same business in a side-street location with a short remaining lease. Where the seller owns the real estate, buyers should evaluate whether to acquire the real estate (locking in occupancy cost) or lease it back (preserving capital for working capital and acquisition financing). The two paths have meaningfully different total economics.